V Square Quantitative Management LLC Decreases Stake in Henry Schein, Inc. (NASDAQ:HSIC)

V Square Quantitative Management LLC lowered its position in Henry Schein, Inc. (NASDAQ:HSIC) by 6.1% in the 4th quarter, HoldingsChannel reports. The fund owned 4,337 shares of the company’s stock after selling 280 shares during the period. V Square Quantitative Management LLC’s holdings in Henry Schein were worth $300,000 as of its most recent filing with the SEC.

Several other large investors also recently added to or reduced their stakes in HSIC. Sumitomo Mitsui DS Asset Management Company Ltd increased its holdings in Henry Schein by 2.7% in the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 12,994 shares of the company’s stock worth $947,000 after acquiring an additional 340 shares during the last quarter. Blue Trust Inc. increased its holdings in Henry Schein by 157.0% in the 3rd quarter. Blue Trust Inc. now owns 2,393 shares of the company’s stock worth $174,000 after acquiring an additional 1,462 shares during the last quarter. Tempus Wealth Planning LLC increased its holdings in Henry Schein by 16.1% in the 3rd quarter. Tempus Wealth Planning LLC now owns 5,348 shares of the company’s stock worth $390,000 after acquiring an additional 741 shares during the last quarter. Assenagon Asset Management S.A. grew its holdings in Henry Schein by 772.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 254,580 shares of the company’s stock valued at $18,559,000 after buying an additional 225,388 shares in the last quarter. Finally, Cromwell Holdings LLC grew its holdings in Henry Schein by 93.4% during the 3rd quarter. Cromwell Holdings LLC now owns 352 shares of the company’s stock valued at $26,000 after buying an additional 170 shares in the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on HSIC. Bank of America raised Henry Schein from an “underperform” rating to a “buy” rating and lifted their target price for the company from $69.00 to $84.00 in a report on Monday, January 6th. Mizuho began coverage on Henry Schein in a report on Wednesday, December 4th. They set a “neutral” rating and a $75.00 target price for the company. Jefferies Financial Group lifted their target price on Henry Schein from $77.00 to $80.00 and gave the company a “hold” rating in a report on Thursday, January 23rd. Wells Fargo & Company began coverage on Henry Schein in a report on Friday. They set an “equal weight” rating and a $80.00 target price for the company. Finally, Barrington Research lifted their target price on Henry Schein from $82.00 to $90.00 and gave the company an “outperform” rating in a report on Thursday, January 30th. Eight research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Henry Schein currently has an average rating of “Moderate Buy” and an average target price of $80.09.

Henry Schein Stock Performance

NASDAQ:HSIC opened at $76.00 on Monday. The business has a 50 day moving average of $74.01 and a 200 day moving average of $72.00. The company has a market capitalization of $9.48 billion, a price-to-earnings ratio of 31.28, a PEG ratio of 2.21 and a beta of 0.91. Henry Schein, Inc. has a 1-year low of $63.67 and a 1-year high of $82.63. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 0.82.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.